These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 29051180)

  • 1. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
    Wei AH; Tiong IS
    Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How I treat acute myeloid leukemia in the era of new drugs.
    DiNardo CD; Wei AH
    Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax-based therapies for acute myeloid leukemia.
    Guerra VA; DiNardo C; Konopleva M
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
    Stone RM
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
    Talati C; Sweet K
    Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A concise review of BCL-2 inhibition in acute myeloid leukemia.
    Yogarajah M; Stone RM
    Expert Rev Hematol; 2018 Feb; 11(2):145-154. PubMed ID: 29264938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
    Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
    Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
    [No Abstract]   [Full Text] [Related]  

  • 9. ＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
    Naoe T
    Nagoya J Med Sci; 2020 May; 82(2):151-160. PubMed ID: 32581396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent and combination biologics in acute myeloid leukemia.
    Richard-Carpentier G; DiNardo CD
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):548-556. PubMed ID: 31808888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What to use to treat AML: the role of emerging therapies.
    Thol F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and predictions: AML in 2018.
    Rowe JM
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In brief: Two new drugs for AML.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [What is recommended in the treatment of acute myeloid leukemia?].
    Thol F
    Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First new drug approval for AML in 15 years.
    Sheridan C
    Nat Biotechnol; 2017 Aug; 35(8):696-698. PubMed ID: 28787411
    [No Abstract]   [Full Text] [Related]  

  • 17. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
    Gbadamosi M; Meshinchi S; Lamba JK
    Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
    Röllig C; Schliemann C; Ruhnke L; Fransecky L; Heydrich BN; Hanoun M; Noppeney R; Schäfer-Eckart K; Wendelin K; Mikesch JH; Middeke JM; Reimann M; Fiebig F; Zukunft S; Wermke M; Serve H; Platzbecker U; Müller-Tidow C; Baldus CD; Bornhäuser M
    Br J Haematol; 2024 Jun; 204(6):2254-2258. PubMed ID: 38593353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.